

Heng Sheng Sow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9165305/publications.pdf>

Version: 2024-02-01

9
papers

177
citations

1163117
8
h-index

1474206
9
g-index

9
all docs

9
docs citations

9
times ranked

368
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Inhibition of TGF- β 2 Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. <i>Cells</i> , 2019, 8, 320.	4.1	82
2	IgE Antibodies against Cancer: Efficacy and Safety. <i>Antibodies</i> , 2020, 9, 55.	2.5	17
3	A Restricted Role for Fc γ 3R in the Regulation of Adaptive Immunity. <i>Journal of Immunology</i> , 2018, 200, 2615-2626.	0.8	14
4	AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1985-1989.	5.7	14
5	Fc γ 3R interaction is not required for effective anti-PD-1 immunotherapy but can add additional benefit depending on the tumor model. <i>International Journal of Cancer</i> , 2019, 144, 345-354.	5.1	12
6	High Fc γ 3R Expression on Intratumoral Macrophages Enhances Tumor-Targeting Antibody Therapy. <i>Journal of Immunology</i> , 2018, 201, 3741-3749.	0.8	11
7	<i>In vivo</i> safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. <i>MAbs</i> , 2020, 12, 1685349.	5.2	11
8	Fc γ 3RI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines. <i>Oncotarget</i> , 2018, 9, 29392-29402.	1.8	10
9	Immunogenicity of rat-neu+ mouse mammary tumours determines the T cell-dependent therapeutic efficacy of anti-neu monoclonal antibody treatment. <i>Scientific Reports</i> , 2020, 10, 3933.	3.3	6